240 related articles for article (PubMed ID: 16904818)
1. Zonal origin of localized prostate cancer does not affect the rate of biochemical recurrence after radical prostatectomy.
Chun FK; Briganti A; Jeldres C; Erbersdobler A; Schlomm T; Steuber T; Gallina A; Walz J; Perrotte P; Huland H; Graefen M; Karakiewicz PI
Eur Urol; 2007 Apr; 51(4):949-55; discussion 955. PubMed ID: 16904818
[TBL] [Abstract][Full Text] [Related]
2. Biochemical recurrence following radical prostatectomy: a comparison between prostate cancers located in different anatomical zones.
Augustin H; Erbersdobler A; Graefen M; Fernandez S; Palisaar J; Huland H; Hammerer P
Prostate; 2003 Apr; 55(1):48-54. PubMed ID: 12640660
[TBL] [Abstract][Full Text] [Related]
3. Analysis of differences in clinicopathological features between prostate cancers located in the transition and peripheral zones.
Sakai I; Harada K; Kurahashi T; Yamanaka K; Hara I; Miyake H
Int J Urol; 2006 Apr; 13(4):368-72. PubMed ID: 16734852
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the biological features between prostate cancers arising in the transition and peripheral zones.
Sakai I; Harada K; Hara I; Eto H; Miyake H
BJU Int; 2005 Sep; 96(4):528-32. PubMed ID: 16104904
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancers of different zonal origin: clinicopathological characteristics and biochemical outcome after radical prostatectomy.
Iremashvili V; Pelaez L; Jordá M; Manoharan M; Rosenberg DL; Soloway MS
Urology; 2012 Nov; 80(5):1063-9. PubMed ID: 23107397
[TBL] [Abstract][Full Text] [Related]
6. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
7. Prostate carcinoma with positive margins at radical prostatectomy: role of tumour zonal origin in biochemical recurrence.
O'Neil LM; Walsh S; Cohen RJ; Lee S
BJU Int; 2015 Oct; 116 Suppl 3():42-8. PubMed ID: 26218868
[TBL] [Abstract][Full Text] [Related]
8. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Partin AW
J Urol; 2006 Oct; 176(4 Pt 1):1404-8. PubMed ID: 16952644
[TBL] [Abstract][Full Text] [Related]
9. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
[TBL] [Abstract][Full Text] [Related]
10. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?
Thompson RH; Blute ML; Slezak JM; Bergstralh EJ; Leibovich BC
J Urol; 2007 Aug; 178(2):459-63; discussion 463. PubMed ID: 17561132
[TBL] [Abstract][Full Text] [Related]
11. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
12. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
[TBL] [Abstract][Full Text] [Related]
13. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy.
Schroeck FR; Sun L; Freedland SJ; Jayachandran J; Robertson CN; Moul JW
Prostate Cancer Prostatic Dis; 2008; 11(4):371-6. PubMed ID: 18427570
[TBL] [Abstract][Full Text] [Related]
14. Transition zone cancers undermine the predictive accuracy of Partin table stage predictions.
Steuber T; Karakiewicz PI; Augustin H; Erbersdobler A; Lange I; Haese A; Chun KH; Walz J; Graefen M; Huland H
J Urol; 2005 Mar; 173(3):737-41. PubMed ID: 15711259
[TBL] [Abstract][Full Text] [Related]
15. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.
Cookson MS; Aus G; Burnett AL; Canby-Hagino ED; D'Amico AV; Dmochowski RR; Eton DT; Forman JD; Goldenberg SL; Hernandez J; Higano CS; Kraus SR; Moul JW; Tangen C; Thrasher JB; Thompson I
J Urol; 2007 Feb; 177(2):540-5. PubMed ID: 17222629
[TBL] [Abstract][Full Text] [Related]
16. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms.
Shariat SF; Park S; Trinh QD; Roehrborn CG; Slawin KM; Karakiewicz PI
J Urol; 2007 Oct; 178(4 Pt 1):1229-36; discussion 1236-7. PubMed ID: 17698116
[TBL] [Abstract][Full Text] [Related]
18. Cross-cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy.
Rouprêt M; Hupertan V; Comperat E; Drouin SJ; Phé V; Xylinas E; Demanse D; Sibony M; Richard F; Cussenot O
BJU Int; 2009 Sep; 104(6):813-7; discussion 817-8. PubMed ID: 19254280
[TBL] [Abstract][Full Text] [Related]
19. The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.
Kositsawat J; Flanigan RC; Meydani M; Choi YK; Freeman VL
J Urol; 2007 Dec; 178(6):2391-6; discussion 2396. PubMed ID: 17936811
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
